The estimated Net Worth of Michael I Ruxin is at least 15.6 千$ dollars as of 4 November 2010. Michael Ruxin owns over 215 units of Haemonetics stock worth over 15,577$ and over the last 15 years Michael sold HAE stock worth over 0$.
Michael has made over 1 trades of the Haemonetics stock since 2010, according to the Form 4 filled with the SEC. Most recently Michael bought 215 units of HAE stock worth 9,963$ on 4 November 2010.
The largest trade Michael's ever made was buying 215 units of Haemonetics stock on 4 November 2010 worth over 9,963$. On average, Michael trades about 108 units every 0 days since 2010. As of 4 November 2010 Michael still owns at least 215 units of Haemonetics stock.
You can see the complete history of Michael Ruxin stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is 400 WOOD ROAD, , BRAINTREE, MA, 02184.
Over the last 21 years, insiders at Haemonetics have traded over 82,114,016$ worth of Haemonetics stock and bought 334,931 units worth 14,646,550$ . The most active insiders traders include Paul Black、Robert E Abernathy、Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of 539,753$. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth 393,039$.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: